Danaher Corporation

Q3 2026 headline performance beat expectations (good / “what to note”) - Sales: $6.6B - Core revenue growth (ex respiratory): +5.5% YoY (improved ~100 bps vs Q2) - Respiratory revenue: slight beat but still a ~250 bps headwind to core growth; overall core growth ~+3% - Profitability: Adjusted operating margin ~29% (+110 bps YoY) and nearly 30% - EPS: Adjusted diluted EPS $2.11 (+~11.5% YoY) - Cash flow quality: Free cash flow $1.6B in Q3; $4.0B YTD; FCF / net income conversion ~128% (differentiated earnings quality)

Segment momentum and demand backdrop (good + some nuance) - Biotechnology: +5% core; Bioprocessing toward upper end of mid-single digits; orders +mid-teens (notably upstream consumables/reagents); confidence in sustainable high single-digit long-term growth. - Life Sciences: +4.5% core - Applied filtration mid-single digits (aerospace & microelectronics robust) - Instruments mid-single digits (SCIEX demand improving; Beckman Coulter automation + AI-enabled solutions traction) - Diagnostics (ex respiratory): +7% core; respiratory about $350M, down YoY due to lower infection rates (but modestly ahead of expectations from pre-season purchasing) - Leica momentum in digital pathology + advanced staining - Beckman Coulter Diagnostics: best core growth quarter in >2 years (DxI 9000; easier China policy headwinds)

Guidance / forecasts for Q4 and full-year 2026 (key investor expectations) - Q4 2026 core growth (ex respiratory): 4%–5% - Q4 respiratory headwind: ~150 bps - Q4 adjusted operating margin: ~29.5% - Full-year 2026 adjusted diluted EPS guidance raised: $8.57–$8.62 (from prior $8.45–$8.60), implying double-digit YoY EPS growth - 2027 framing (not full formal guidance yet): management suggests starting point of ~4%–5% core growth (ex respiratory)